All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, March 5, 2021
Home » Blogs » BioWorld Perspectives » Send Me an Angel: More VC Alternatives on the Rise

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

Send Me an Angel: More VC Alternatives on the Rise

Nov. 28, 2011
By Trista Morrison
No Comments

It seems to me that an increasing number of start-ups have been boot-strapping their way through preclinical without venture capital lately.

I have no quantitative data to back this up. But it’s a feeling I had earlier this year, too, as we reported on some big non-VC start-up rounds, like Ascletis Inc.’s $100 million raised largely from high net worth investors in China, and Acetylon Pharmaceuticals Inc.’s $27 million Series B round raised in $1 million chunks from private individuals. We even made this subject the topic of BioWorld’s BIO 2011 panel.

The trend appears to be continuing. Avaxia Biologics Inc. just raised $2.2 million in Series A financing from angels. Karyopharm Therapeutics Inc. closed a $10 million Series A2 round led by Chione Ltd., a Greek investment vehicle for a high net worth individual. Quanticel Pharmaceuticals Inc. raised $45 million through a unique deal with Celgene Corp. and Versant Ventures. And last month, Russia's state-owned investment firm Rusnano made some big bets on Selecta Biosciences Inc. and Bind Biosciences Inc.

Non-VC deals are still the minority, but they seem to be ever so slightly more common than in the past. I’m guessing this is a trend born of necessity – with so many VCs pulling back (Prospect Ventures, Scale Venture Partners, etc.), start-ups might be forced to seek alternatives more often than in the past.

But even so, the fact that alternatives exist is encouraging. I’m a self-professed optimist on biotech, but I’m even further encouraged by the bills moving through Congress that could boost small company fundraising options. For start-ups in particular, H.R. 2930 could be good news, as it would let private companies raise up to $2 million through crowd funding, essentially opening the private markets to non-accredited investors. For all the details, don’t miss this week’s BioWorld Insight.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 4.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 4.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing